Loading…

CdGAP/ARHGAP31 is regulated by RSK phosphorylation and binding to 14-3-3β adaptor protein

Cdc42 GTPase-activating protein (CdGAP, also named ARHGAP31) is a negative regulator of the GTPases Rac1 and Cdc42. Associated with the rare developmental disorder Adams-Oliver Syndrome (AOS), CdGAP is critical for embryonic vascular development and VEGF-mediated angiogenesis. Moreover, CdGAP is an...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2018-02, Vol.9 (14), p.11646-11664
Main Authors: Ouadda, Ali Ben Djoudi, He, Yi, Calabrese, Viviane, Ishii, Hidetaka, Chidiac, Rony, Gratton, Jean-Philippe, Roux, Philippe P, Lamarche-Vane, Nathalie
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c271t-ee00e8149724bab4d38488dce8376390e081edeb93edbff6150de8d2c7956b173
cites cdi_FETCH-LOGICAL-c271t-ee00e8149724bab4d38488dce8376390e081edeb93edbff6150de8d2c7956b173
container_end_page 11664
container_issue 14
container_start_page 11646
container_title Oncotarget
container_volume 9
creator Ouadda, Ali Ben Djoudi
He, Yi
Calabrese, Viviane
Ishii, Hidetaka
Chidiac, Rony
Gratton, Jean-Philippe
Roux, Philippe P
Lamarche-Vane, Nathalie
description Cdc42 GTPase-activating protein (CdGAP, also named ARHGAP31) is a negative regulator of the GTPases Rac1 and Cdc42. Associated with the rare developmental disorder Adams-Oliver Syndrome (AOS), CdGAP is critical for embryonic vascular development and VEGF-mediated angiogenesis. Moreover, CdGAP is an essential component in the synergistic interaction between TGFβ and ErbB-2 signaling pathways during breast cancer cell migration and invasion, and is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer. CdGAP is highly phosphorylated on serine and threonine residues in response to growth factors and is a substrate of ERK1/2 and GSK-3. Here, we identified Ser1093 and Ser1163 in the C-terminal region of CdGAP, which are phosphorylated by RSK in response to phorbol ester. These phospho-residues create docking sites for binding to 14-3-3 adaptor proteins. The interaction between CdGAP and 14-3-3 proteins inhibits the GAP activity of CdGAP and sequesters CdGAP into the cytoplasm. Consequently, the nucleocytoplasmic shuttling of CdGAP is inhibited and CdGAP-induced cell rounding is abolished. In addition, 14-3-3β inhibits the ability of CdGAP to repress the E-cadherin promoter and to induce cell migration. Finally, we show that 14-3-3β is unable to regulate the activity and subcellular localization of the AOS-related mutant proteins lacking these phospho-residues. Altogether, we provide a novel mechanism of regulation of CdGAP activity and localization, which impacts directly on a better understanding of the role of CdGAP as a promoter of breast cancer and in the molecular causes of AOS.
doi_str_mv 10.18632/oncotarget.24126
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5837747</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2014949161</sourcerecordid><originalsourceid>FETCH-LOGICAL-c271t-ee00e8149724bab4d38488dce8376390e081edeb93edbff6150de8d2c7956b173</originalsourceid><addsrcrecordid>eNpVUdtqGzEQFaUhMUk-IC9Fj33ZWLfdlV4KxjRxaKAhaV_yIrSrsaOylraSHPBv5UP6TVXuzsAww8yccwYOQieUnFLZcDYNvg_ZxBXkUyYoaz6hCVVCVayu-eed_gAdp_SHlKhFK5naRwdM1aJWrJ2g27k9n11NZ9eLUjjFLuEIq81gMljcbfH1zQ883oVUMm7L1AWPjS8r563zK5wDpqLiFf_3gI01Yw4RjzFkcP4I7S3NkOD4pR6i32fff80X1eXP84v57LLqWUtzBUAISCpUy0RnOmG5FFLaHiRvG64IEEnBQqc42G65bGhNLEjL-lbVTUdbfoi-PfOOm24NBehzNIMeo1ubuNXBOP1x492dXoV7XReFVjwSfH0hiOHvBlLWa5d6GAbjIWySZqR8JxRtaDmlz6d9DClFWL7JUKKfbNHvtugnWwrmy-5_b4hXE_h_VeiLxw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2014949161</pqid></control><display><type>article</type><title>CdGAP/ARHGAP31 is regulated by RSK phosphorylation and binding to 14-3-3β adaptor protein</title><source>PubMed Central</source><creator>Ouadda, Ali Ben Djoudi ; He, Yi ; Calabrese, Viviane ; Ishii, Hidetaka ; Chidiac, Rony ; Gratton, Jean-Philippe ; Roux, Philippe P ; Lamarche-Vane, Nathalie</creator><creatorcontrib>Ouadda, Ali Ben Djoudi ; He, Yi ; Calabrese, Viviane ; Ishii, Hidetaka ; Chidiac, Rony ; Gratton, Jean-Philippe ; Roux, Philippe P ; Lamarche-Vane, Nathalie</creatorcontrib><description>Cdc42 GTPase-activating protein (CdGAP, also named ARHGAP31) is a negative regulator of the GTPases Rac1 and Cdc42. Associated with the rare developmental disorder Adams-Oliver Syndrome (AOS), CdGAP is critical for embryonic vascular development and VEGF-mediated angiogenesis. Moreover, CdGAP is an essential component in the synergistic interaction between TGFβ and ErbB-2 signaling pathways during breast cancer cell migration and invasion, and is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer. CdGAP is highly phosphorylated on serine and threonine residues in response to growth factors and is a substrate of ERK1/2 and GSK-3. Here, we identified Ser1093 and Ser1163 in the C-terminal region of CdGAP, which are phosphorylated by RSK in response to phorbol ester. These phospho-residues create docking sites for binding to 14-3-3 adaptor proteins. The interaction between CdGAP and 14-3-3 proteins inhibits the GAP activity of CdGAP and sequesters CdGAP into the cytoplasm. Consequently, the nucleocytoplasmic shuttling of CdGAP is inhibited and CdGAP-induced cell rounding is abolished. In addition, 14-3-3β inhibits the ability of CdGAP to repress the E-cadherin promoter and to induce cell migration. Finally, we show that 14-3-3β is unable to regulate the activity and subcellular localization of the AOS-related mutant proteins lacking these phospho-residues. Altogether, we provide a novel mechanism of regulation of CdGAP activity and localization, which impacts directly on a better understanding of the role of CdGAP as a promoter of breast cancer and in the molecular causes of AOS.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.24126</identifier><identifier>PMID: 29545927</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Research Paper</subject><ispartof>Oncotarget, 2018-02, Vol.9 (14), p.11646-11664</ispartof><rights>Copyright: © 2018 Ouadda et al. 2018</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c271t-ee00e8149724bab4d38488dce8376390e081edeb93edbff6150de8d2c7956b173</citedby><cites>FETCH-LOGICAL-c271t-ee00e8149724bab4d38488dce8376390e081edeb93edbff6150de8d2c7956b173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837747/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837747/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29545927$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ouadda, Ali Ben Djoudi</creatorcontrib><creatorcontrib>He, Yi</creatorcontrib><creatorcontrib>Calabrese, Viviane</creatorcontrib><creatorcontrib>Ishii, Hidetaka</creatorcontrib><creatorcontrib>Chidiac, Rony</creatorcontrib><creatorcontrib>Gratton, Jean-Philippe</creatorcontrib><creatorcontrib>Roux, Philippe P</creatorcontrib><creatorcontrib>Lamarche-Vane, Nathalie</creatorcontrib><title>CdGAP/ARHGAP31 is regulated by RSK phosphorylation and binding to 14-3-3β adaptor protein</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>Cdc42 GTPase-activating protein (CdGAP, also named ARHGAP31) is a negative regulator of the GTPases Rac1 and Cdc42. Associated with the rare developmental disorder Adams-Oliver Syndrome (AOS), CdGAP is critical for embryonic vascular development and VEGF-mediated angiogenesis. Moreover, CdGAP is an essential component in the synergistic interaction between TGFβ and ErbB-2 signaling pathways during breast cancer cell migration and invasion, and is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer. CdGAP is highly phosphorylated on serine and threonine residues in response to growth factors and is a substrate of ERK1/2 and GSK-3. Here, we identified Ser1093 and Ser1163 in the C-terminal region of CdGAP, which are phosphorylated by RSK in response to phorbol ester. These phospho-residues create docking sites for binding to 14-3-3 adaptor proteins. The interaction between CdGAP and 14-3-3 proteins inhibits the GAP activity of CdGAP and sequesters CdGAP into the cytoplasm. Consequently, the nucleocytoplasmic shuttling of CdGAP is inhibited and CdGAP-induced cell rounding is abolished. In addition, 14-3-3β inhibits the ability of CdGAP to repress the E-cadherin promoter and to induce cell migration. Finally, we show that 14-3-3β is unable to regulate the activity and subcellular localization of the AOS-related mutant proteins lacking these phospho-residues. Altogether, we provide a novel mechanism of regulation of CdGAP activity and localization, which impacts directly on a better understanding of the role of CdGAP as a promoter of breast cancer and in the molecular causes of AOS.</description><subject>Research Paper</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpVUdtqGzEQFaUhMUk-IC9Fj33ZWLfdlV4KxjRxaKAhaV_yIrSrsaOylraSHPBv5UP6TVXuzsAww8yccwYOQieUnFLZcDYNvg_ZxBXkUyYoaz6hCVVCVayu-eed_gAdp_SHlKhFK5naRwdM1aJWrJ2g27k9n11NZ9eLUjjFLuEIq81gMljcbfH1zQ883oVUMm7L1AWPjS8r563zK5wDpqLiFf_3gI01Yw4RjzFkcP4I7S3NkOD4pR6i32fff80X1eXP84v57LLqWUtzBUAISCpUy0RnOmG5FFLaHiRvG64IEEnBQqc42G65bGhNLEjL-lbVTUdbfoi-PfOOm24NBehzNIMeo1ubuNXBOP1x492dXoV7XReFVjwSfH0hiOHvBlLWa5d6GAbjIWySZqR8JxRtaDmlz6d9DClFWL7JUKKfbNHvtugnWwrmy-5_b4hXE_h_VeiLxw</recordid><startdate>20180220</startdate><enddate>20180220</enddate><creator>Ouadda, Ali Ben Djoudi</creator><creator>He, Yi</creator><creator>Calabrese, Viviane</creator><creator>Ishii, Hidetaka</creator><creator>Chidiac, Rony</creator><creator>Gratton, Jean-Philippe</creator><creator>Roux, Philippe P</creator><creator>Lamarche-Vane, Nathalie</creator><general>Impact Journals LLC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180220</creationdate><title>CdGAP/ARHGAP31 is regulated by RSK phosphorylation and binding to 14-3-3β adaptor protein</title><author>Ouadda, Ali Ben Djoudi ; He, Yi ; Calabrese, Viviane ; Ishii, Hidetaka ; Chidiac, Rony ; Gratton, Jean-Philippe ; Roux, Philippe P ; Lamarche-Vane, Nathalie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c271t-ee00e8149724bab4d38488dce8376390e081edeb93edbff6150de8d2c7956b173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Research Paper</topic><toplevel>online_resources</toplevel><creatorcontrib>Ouadda, Ali Ben Djoudi</creatorcontrib><creatorcontrib>He, Yi</creatorcontrib><creatorcontrib>Calabrese, Viviane</creatorcontrib><creatorcontrib>Ishii, Hidetaka</creatorcontrib><creatorcontrib>Chidiac, Rony</creatorcontrib><creatorcontrib>Gratton, Jean-Philippe</creatorcontrib><creatorcontrib>Roux, Philippe P</creatorcontrib><creatorcontrib>Lamarche-Vane, Nathalie</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ouadda, Ali Ben Djoudi</au><au>He, Yi</au><au>Calabrese, Viviane</au><au>Ishii, Hidetaka</au><au>Chidiac, Rony</au><au>Gratton, Jean-Philippe</au><au>Roux, Philippe P</au><au>Lamarche-Vane, Nathalie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CdGAP/ARHGAP31 is regulated by RSK phosphorylation and binding to 14-3-3β adaptor protein</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2018-02-20</date><risdate>2018</risdate><volume>9</volume><issue>14</issue><spage>11646</spage><epage>11664</epage><pages>11646-11664</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>Cdc42 GTPase-activating protein (CdGAP, also named ARHGAP31) is a negative regulator of the GTPases Rac1 and Cdc42. Associated with the rare developmental disorder Adams-Oliver Syndrome (AOS), CdGAP is critical for embryonic vascular development and VEGF-mediated angiogenesis. Moreover, CdGAP is an essential component in the synergistic interaction between TGFβ and ErbB-2 signaling pathways during breast cancer cell migration and invasion, and is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer. CdGAP is highly phosphorylated on serine and threonine residues in response to growth factors and is a substrate of ERK1/2 and GSK-3. Here, we identified Ser1093 and Ser1163 in the C-terminal region of CdGAP, which are phosphorylated by RSK in response to phorbol ester. These phospho-residues create docking sites for binding to 14-3-3 adaptor proteins. The interaction between CdGAP and 14-3-3 proteins inhibits the GAP activity of CdGAP and sequesters CdGAP into the cytoplasm. Consequently, the nucleocytoplasmic shuttling of CdGAP is inhibited and CdGAP-induced cell rounding is abolished. In addition, 14-3-3β inhibits the ability of CdGAP to repress the E-cadherin promoter and to induce cell migration. Finally, we show that 14-3-3β is unable to regulate the activity and subcellular localization of the AOS-related mutant proteins lacking these phospho-residues. Altogether, we provide a novel mechanism of regulation of CdGAP activity and localization, which impacts directly on a better understanding of the role of CdGAP as a promoter of breast cancer and in the molecular causes of AOS.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>29545927</pmid><doi>10.18632/oncotarget.24126</doi><tpages>19</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1949-2553
ispartof Oncotarget, 2018-02, Vol.9 (14), p.11646-11664
issn 1949-2553
1949-2553
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5837747
source PubMed Central
subjects Research Paper
title CdGAP/ARHGAP31 is regulated by RSK phosphorylation and binding to 14-3-3β adaptor protein
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T16%3A53%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CdGAP/ARHGAP31%20is%20regulated%20by%20RSK%20phosphorylation%20and%20binding%20to%2014-3-3%CE%B2%20adaptor%20protein&rft.jtitle=Oncotarget&rft.au=Ouadda,%20Ali%20Ben%20Djoudi&rft.date=2018-02-20&rft.volume=9&rft.issue=14&rft.spage=11646&rft.epage=11664&rft.pages=11646-11664&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.24126&rft_dat=%3Cproquest_pubme%3E2014949161%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c271t-ee00e8149724bab4d38488dce8376390e081edeb93edbff6150de8d2c7956b173%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2014949161&rft_id=info:pmid/29545927&rfr_iscdi=true